4.2 Article

A novel immunogenic spore coat-associated protein in Bacillus anthracis: Characterization via proteomics approaches and a vector-based vaccine system

Journal

PROTEIN EXPRESSION AND PURIFICATION
Volume 57, Issue 1, Pages 72-80

Publisher

ACADEMIC PRESS INC ELSEVIER SCIENCE
DOI: 10.1016/j.pep.2007.08.016

Keywords

immunogenic; spore coat; Bacillus anthracis proteomics; vector; vaccine

Funding

  1. NATIONAL CENTER FOR RESEARCH RESOURCES [R21RR022754] Funding Source: NIH RePORTER
  2. NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P30AI036214, U54AI057157, R01AI067395, R21AI058002] Funding Source: NIH RePORTER
  3. NCRR NIH HHS [R21 RR022754-01, R21 RR022754-02, R21 RR022754] Funding Source: Medline
  4. NIAID NIH HHS [R21 AI058002-02, R21 AI058002-03, R01 AI067395-02, U54 AI057157, R01 AI067395-03, R01 AI067395-01, P30-AI36214-12S1, R21 AI058002, 5 U54 AI057157-02, P30 AI036214, R01-AI067395-01, R01 AI067395, R21 AI058002-01] Funding Source: Medline
  5. PHS HHS [R21-R022754-01, R21-I58002-01] Funding Source: Medline

Ask authors/readers for more resources

New generation anthrax vaccines have been actively explored with the aim of enhancing efficacies and decreasing undesirable side effects that could be caused by licensed vaccines. Targeting novel antigens and/or eliminating the requirements for multiple needle injections and adjuvants are major objectives in the development of new anthrax vaccines. Using proteomics approaches, we identified a spore coat-associated protein (SCAP) in Bacillus anthracis. An Escherichia coli vector-based vaccine system was used to determine the immunogenicity of SCAP. Mice generated detectable SCAP antibodies three weeks after intranasal immunization with an intact particle of ultraviolet (UV)-irradiated E coli vector overproducing SCAP. The production of SCAT antibodies was detected via western blotting and SCAP-spotted antigen-arrays. The adjuvant effect of a UV-irradiated E. coli vector eliminates the necessity of boosting and the use of other immunomodulators which will foster the screening and manufacturing of new generation anthrax vaccines. More importantly, the immunogenic SCAP may potentially be a new candidate for the development of anthrax vaccines. Published by Elsevier Inc.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.2
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available